Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome

Antonio Gasbarrini, Massimo Siciliano, Valeria Cento, Daniele Di Paolo, Domenico Di Carlo, Valeria Micheli, Monica Tontodonati, Francesco De Leonardis, Marianna Aragri, Francesco Paolo Antonucci, Velia Chiara Di Maio, Alessandro Mancon, Ilaria Lenci, Alessandra Manunta, Gloria Taliani, Antonio Di Biagio, Laura Ambra Nicolini, Lorenzo Nosotti, Cesare Sarrecchia, Simona LandonioAdriano Pellicelli, Jacopo Vecchiet, Carlo Federico Magni, Sergio Babudieri, Maria Stella Mura, Massimo Andreoni, Giustino Parruti, Giuliano Rizzardini, Mario Angelico, Carlo Federico Perno, Francesca Ceccherini-Silberstein

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Triple therapy with telaprevir/boceprevir+pegylated-interferon+ribavirin can achieve excellent antiviral efficacy, but it can be burdened with resistance development at failure.
Original languageEnglish
Pages (from-to)N/A-N/A
JournalDIGESTIVE AND LIVER DISEASE
DOIs
Publication statusPublished - 2014

Keywords

  • Early response
  • NS3 protease inhibitors
  • Viral kinetics
  • Virological failure

Fingerprint

Dive into the research topics of 'Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome'. Together they form a unique fingerprint.

Cite this